Lipocine Inc. (LPCN)
| Market Cap | 18.22M +2.9% |
| Revenue (ttm) | 2.00M -45.5% |
| Net Income | -11.43M |
| EPS | -1.97 |
| Shares Out | 8.03M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 35,339 |
| Open | 2.290 |
| Previous Close | 2.330 |
| Day's Range | 2.260 - 2.340 |
| 52-Week Range | 1.810 - 12.370 |
| Beta | 0.50 |
| Analysts | Hold |
| Price Target | n/a |
| Earnings Date | May 7, 2026 |
About LPCN
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. It also develops LPCN 1154 (BRLIZIO), an oral neuro-steroid in a Phase 3 pivotal trial for postpartum depression; LPCN 1148, a prodrug of testosterone and testosterone laurate that has completed a Phase 2 trial for the management of decompensated cirrhosis; LPCN 1107, an... [Read more]
Financial Performance
Financial StatementsNews
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026
SALT LAKE CITY, May 7, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral deli...
Lipocine price target lowered to $6 from $11 at Alliance Global
Alliance Global lowered the firm’s price target on Lipocine (LPCN) to $6 from $11 and keeps a Buy rating on the shares, noting that the company announced on April 2…
Lipocine Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, April 06, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Lipocine Inc. (NASDAQ: LPCN). The investigation focuses on Lipocine's exe...
Lipocine downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright downgraded Lipocine (LPCN) to Neutral from Buy without a price target after LPCN 1154 did not meet the efficacy endpoint in the Phase 3 trial. The firm cites…
Lipocine’s LPCN 1154 did not meet endpoint in postpartum depression trial
Lipocine (LPCN) announced topline results from its Phase 3 placebo-controlled trial evaluating LPCN 1154 – oral brexanolone – for the treatment of postpartum depression, or PPD. LPCN 1154 did not…
Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression
In the Phase 3 study population (N=90) of patients with PPD, LPCN 1154 did not show a statistically significant reduction from baseline in HAM-D17 total score compared to placebo at hour 60 (primary e...
Lipocine price target raised to $11 from $6.75 at Alliance Global
Alliance Global raised the firm’s price target on Lipocine (LPCN) to $11 from $6.75 and keeps a Buy rating on the shares. Q4 earnings were within the range of expectations,…
Lipocine Announces Financial Results for the Full Year Ended December 31, 2025
SALT LAKE CITY, March 10, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral d...
Lipocine announces last patient visit in Phase 3 trial of LPCN 1154
Lipocine (LPCN) announced that the last patient has completed the final study visit in its Phase 3 clinical trial evaluating LPCN 1154 for the treatment of postpartum depression. The randomized,…
Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD)
SALT LAKE CITY, Feb. 18, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective ora...
Lipocine price target raised to $15 from $7 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Lipocine (LPCN) to $15 from $7 and keeps a Buy rating on the shares. The firm says LPCN 1154 showed a favorable…
Lipocine completes enrollment, dosing in Phase 3 trial of LPCN 1154
Lipocine (LPCN) announced that enrollment and participant dosing have been completed in its Phase 3 clinical trial evaluating LPCN 1154 for the treatment of postpartum depression. “We look forward to…
Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
SALT LAKE CITY, Jan. 20, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective ora...
Lipocine: DSMB recommended Phase 3 LPCN 1154 continue as planned
Lipocine (LPCN) announced the completion of a scheduled independent Data Safety Monitoring Board review of its ongoing Phase 3 clinical trial evaluating LPCN 1154 for the rapid relief treatment of…
Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
Company on track to report topline results early in the second quarter of 2026 Second planned Data and Safety Monitoring Board (DSMB) meeting evaluated all available safety data for the 82 randomized ...
Lipocine ‘s PPD Phase 3 study hits 80% enrollment milestone
Lipocine (LPCN) announced 80% completion of enrollment in the ongoing Phase 3 clinical trial evaluating LPCN 1154, or oral brexanolone, for the rapid relief treatment of PPD, with 66 of…
Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone
Second Drug Safety Monitoring Board (DSMB) meeting update planned for mid-January 2026 Topline results on track for the second quarter of 2026 SALT LAKE CITY , Dec. 16, 2025 /PRNewswire/ -- Lipocine I...
Lipocine reports ‘promising’ safety profile in Phase 3 trial of LPCN 1154
Lipocine (LPCN) announced the completion of a scheduled independent Data Safety Monitoring Board review of its ongoing Phase 3 clinical trial evaluating LPCN 1154 for the rapid relief treatment of…
Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
Per the Drug Safety Monitoring Board (DSMB) meeting evaluating one-third of planned participants, study to continue as planned More than half of planned participants have completed dosing with no dose...
Lipocine price target lowered to $7 from $8 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Lipocine (LPCN) to $7 from $8 and keeps a Buy rating on the shares following the Q3 report.
Lipocine reports Q3 EPS (59c) vs. (44c) last year
Reports Q3 revenue $114.57M vs. $0 last year. As of September 30, 2025, Lipocine (LPCN) had $15.1M of unrestricted cash, cash equivalents and marketable investment securities compared to $21.6M at…
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025
SALT LAKE CITY , Nov. 6, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral de...
Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek®
SALT LAKE CITY , Nov. 4, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective ora...
Lipocine provides update on Phase 3 clinical trial in postpartum depression
Lipocine (LPCN) provided an update on its ongoing pivotal Phase 3 clinical trial evaluating LPCN 1154 for the treatment of postpartum depression, or PPD. The study is progressing on track…
Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD)
One-Third of Patients Randomized; Topline Results Expected in 2Q 2026 DSMB Safety Review Update Planned for 4Q 2025 SALT LAKE CITY , Sept. 30, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biop...